...
首页> 外文期刊>Pharmaceutical research >Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors.
【24h】

Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors.

机译:三酸非肽拮抗剂在表达人AT1受体的CHO细胞中抑制血管紧张素II诱导的肌醇磷酸生成。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The aim of the present work is to describe the inhibitory properties of LY301875 and LY303336, two polysubstituted 4-aminoimidazole AT1 receptor antagonists, on CHO cells expressing human recombinant AT1 receptors. METHODS: The binding of [3H]-angiotensin II to intact cells as well as to angiotensin II induced inositol phosphate accumulation is measured. RESULTS: Both antagonists inhibit specific [3H]-angiotensin II binding to AT1 receptors in these cells, with IC50 values of 5.9 and 5.2 nM, respectively. Preincubation of the cells with LY301875 results in a decline of up to 80% of the maximal angiotensin II-stimulated inositol phosphate (IP) production. A near complete decline of the maximal response is observed for LY303336. This insurmountable inhibition is attenuated for both antagonists when losartan is included during the preincubation of the cells. CONCLUSIONS: Functional recovery experiments, in which antagonist-preincubated cells are washed and exposed to fresh media, suggest that the insurmountable inhibition by LY301875 and LY303336 is related to their relatively slow dissociation from the AT1 receptors. As already described for losartan and the derived insurmountable AT1 antagonists candesartan. EXP3174, and irbesartan, coincubation experiments reveal that LY301875 and LY303336 interact with the AT1 receptor in a manner that is competitive with angiotensin II.
机译:目的:本工作的目的是描述两种多取代的4-氨基咪唑AT1受体拮抗剂LY301875和LY303336对表达人重组AT1受体的CHO细胞的抑制特性。方法:测量[3H]-血管紧张素II与完整细胞的结合以及与血管紧张素II诱导的肌醇磷酸积累的结合。结果:两种拮抗剂均抑制这些细胞中与AT1受体特异性的[3H]-血管紧张素II结合,IC50值分别为5.9和5.2 nM。用LY301875对细胞进行预温育可导致最大血管紧张素II刺激的磷酸肌醇(IP)产量下降多达80%。对于LY303336,观察到最大响应几乎完全下降。当在细胞的预孵育过程中包括氯沙坦时,两种拮抗剂的这种无法克服的抑制作用都会减弱。结论:功能恢复实验中,洗涤了拮抗剂预孵育的细胞并暴露于新鲜培养基中,表明LY301875和LY303336不可逾越的抑制作用与它们相对较慢地与AT1受体解离有关。如已经描述的氯沙坦和衍生的不可克服的AT1拮抗剂坎地沙坦。 EXP3174和厄贝沙坦的共温育实验表明,LY301875和LY303336与AT1受体的相互作用方式与血管紧张素II竞争。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号